John J. Densmore, MD, PhD
Trials of biologic and targeted therapies for hematologic malignancies
Dr. Densmore is studying the application of biologic and targeted therapies for the treatment of hematologic malignancies. As Associate Director of the Hematologic Malignancy program, he is collaborating with Dr. Michael Williams to study novel approaches to leukemia, lymphoma and multiple myeloma. They have recently completed a pilot study of low-dose Rituximab in chronic lymphocytic leukemia in collaboration with Dr. Ronald Taylor that utilized the Biostatistics Core. They are planning the Phase II study to extend the exciting findings of the pilot study, which will again utilize the Biostatistics Core.
Densmore and Williams have developed trials to evaluate novel agents in Non-Hodgkin's Lymphoma (NHL). A trial of Ibritumomab tiuxetan in relapsed Large Cell NHL has been approved by the HIC and is ready to open. A trial of bortezomib and rituximab for relapsed indolent and mantle cell lymphoma has also been developed and is entering the local review process. Both have utilized significant support from the Biostatistics Core. Other trials open within their program include: (1) ECOG studies in multiple myeloma, acute myelogenous leukemia and NHL and (2) pharmaceutical-sponsored studies in indolent NHL.